APLT - Applied Therapeutics' Diabetes-Associated Heart Disease Drug Fails In Phase 3 Study Stock Plunges | Benzinga
Applied Therapeutics Inc (NASDAQ: APLT) released topline results of the ARISE-HF Phase 3 trial of AT-001 (caficrestat) in patients with Diabetic Cardiomyopathy (DbCM) at high risk of progression to overt heart failure.
The study's primary endpoint was stabilization or improvement in cardiac functional capacity as measured by Peak VO2 in patients treated with AT-001 1500mg twice daily (BID) compared to placebo.
The placebo-treated group declined by a mean of -0.31 ml/kg/min over 15 months of treatment, while the AT-001 group remained primarily stable, with a mean change ...